MARC Record from marc_columbia

LEADER: 04298cam a22003738a 4500
001 6730070
005 20221122045206.0
008 071119s2008 njua b 001 0 eng
015 $aGBA795222$2bnb
016 7 $a014407745$2Uk
020 $a9781588296610 (hbk.)
020 $a158829661X (hbk.)
035 $a(OCoLC)ocn181927278
035 $a(OCoLC)181927278
035 $a(NNC)6730070
035 $a6730070
040 $aUKM$cUKM$dBAKER$dNNC-M$dOrLoB-B
082 04 $a616.24$222
090 $aRC776.P87$bP84 2008
245 00 $aPulmonary hypertension /$cby Nicholas S. Hill, Harrison W. Farber.
260 $aTotowa, N.J. :$bHumana ;$aLondon :$bSpringer [distributor],$c2008.
300 $axv, 444 pages :$billustrations ;$c25 cm.
336 $atext$btxt$2rdacontent
337 $aunmediated$bn$2rdamedia
490 1 $aContemporary cardiology
504 $aIncludes bibliographical references and index.
505 00 $g1.$tHistorical perspective : a century of primary (idiopathic) pulmonary hypertension /$rAlfred P. Fishman --$g2.$tClassification of pulmonary hypertension /$rC. William Hargett and Victor F. Tapson --$g3.$tDiagnostic approach to pulmonary arterial hypertension /$rRonald J. Oudiz --$g4.$tPathophysiology of pulmonary arterial hypertension /$rHarrison W. Farber --$g5.$tPulmonary hypertension genes /$rElisabeth Donlevy Willers and Ivan M. Robbins --$g6.$tThe right ventricle in pulmonary hypertension /$rAndrew C. Stone and James R. Klinger --$g7.$tCongenital heart disease associated with pulmonary arterial hypertension /$rMichael J. Landzberg --$g8.$tConnective tissue disease associated pulmonary hypertension /$rKimberly A. Fisher, Nicholas S. Hill and Harrison W. Farber --$g9.$tPulmonary hypertension associated with HIV, liver disease, sarcoidosis, and sickle cell disease /$rKimberly A. Fisher and Elizabeth S. Klings --$g10.$tChronic thromboembolic pulmonary hypertension /$rVictor J. Test, Willam R. Auger and Peter F. Fedullo --$g11.$tGeneral therapeutic approach and traditional therapies /$rNicholas S. Hill and Elizabeth S. Klings --$g12.$tProstacyclin therapy for pulmonary arterial hypertension /$rNicholas S. Hill, Todd F. Vardas and Vallerie McLaughlin --$g13.$tEndothelin and its blockade in pulmonary arterial hypertension /$rDavid Langleben --$g14.$tPDE5 inhibitors and the cGMP pathway in pulmonary arterial hypertension /$rIoana R. Preston --$g15.$tStatins for treatment of pulmonary hypertension /$rJohn L. Faul, Peter N. Kao, Toshihiko Nishimura, Arthur Sung, Hong Hu and Ronald G. Pearl --$g16.$tTransitions and combination therapy for pulmonary arterial hypertension /$rTodd Hirschtritt, M. Kathryn Steiner and Nicholas S. Hill --$g17.$tAcute right ventricular dysfunction : focus on acute cor pulmonale /$rAntoine Vieillard-Baron and Francois Jardin --$g18.$tLung transplantation and atrial septostomy for pulmonary arterial hypertension /$rE. P. Trulock --$g19.$tNew directions in pulmonary hypertension therapy /$rChristopher M. Carlin and Andrew J. Peacock.
520 1 $a"This volume addresses the areas of pathophysiology and therapy of pulmonary hypertension, which have seen exciting developments over the past decade. The discoveries of endothelin overexpression as well as prostacyclin and nitric oxide deficiency in association with pulmonary hypertension have led to important therapeutic insights. In addition, the identification of genes associated with pulmonary hypertension has just begun to open the door to new pathophysiologic insights. The new therapies have led to significant improvements in patient function, quality of life, and survival." "This book will be of interest not only to cardiologists, pulmonary specialists, and rheumatologists, but also to many nurses and pharmacotherapists who are becoming increasingly involved in the therapy of patients with pulmonary hypertension."--BOOK JACKET.
650 0 $aPulmonary hypertension.$0http://id.loc.gov/authorities/subjects/sh85109008
650 12 $aHypertension, Pulmonary.$0https://id.nlm.nih.gov/mesh/D006976
700 1 $aHill, Nicholas S.,$d1949-$0http://id.loc.gov/authorities/names/n00122202
700 1 $aFarber, Harrison W.$0http://id.loc.gov/authorities/names/no2008097379
830 0 $aContemporary cardiology.
852 00 $boff,hsl$hRC776.P87$iP84 2008